RBC Capital Reiterates a Buy Rating on Allergan

By Carrie Williams

In a report issued on July 14, Randall Stanicky from RBC Capital reiterated a Buy rating on Allergan (NYSE: AGN), with a price target of $284. The company’s shares closed on Friday at $245.85.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -7.7% and a 36.7% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Allergan is Moderate Buy and the average price target is $277.38, representing a 12.8% upside.

In a report issued on June 29, Cowen & Co. also reiterated a Buy rating on the stock with a $400 price target.

The company has a one year high of $261.27 and a one year low of $184.50. Currently, Allergan has an average volume of 2.2M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.